Latest Ratios: P/E Ratio -15.0x · EV/EBITDA N/A · ROE -1.6%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $12M | $1.4B | $3.2B | $9.5B | — | — | — | — | — | — |
| Enterprise Value | $-2750639 | $-9842557 | $1.4B | $3.2B | $9.4B | — | — | — | — | — | — |
| P/E Ratio → | -14.96 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.19 | 0.74 | — | — | 35886.73 | — | — | — | — | — | — |
| P/B Ratio | 0.19 | 0.40 | 78.80 | 220.54 | 241.63 | — | — | — | — | — | — |
| P/FCF | 0.24 | 0.15 | — | — | — | — | — | — | — | — | — |
| P/OCF | 0.24 | 0.15 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.63 | — | — | 35800.95 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | -0.13 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -7.2% | -7.2% | — | — | -8095.2% | — | -19319.3% | -401.6% | -771.8% | -261.5% | -415.7% |
| Net Profit Margin | -2.4% | -2.4% | — | — | -8253.7% | — | -15255.2% | -252.8% | -668.3% | -125.6% | -237.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1.6% | -1.6% | -144.3% | -119.6% | -58.1% | -29.4% | -46.3% | -54.5% | -84.6% | -16.5% | -44.1% |
| ROA | -1.0% | -1.0% | -98.6% | -100.1% | -50.8% | -20.3% | -16.0% | -15.9% | -32.8% | -8.0% | -20.9% |
| ROIC | -13.4% | -13.4% | -334.6% | -212.2% | -101.5% | -46.4% | -32.5% | -65.7% | -142.8% | -60.5% | -108.8% |
| ROCE | -3.7% | -3.7% | -129.4% | -109.9% | -52.3% | -31.4% | -27.0% | -32.6% | -46.3% | -19.4% | -43.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | 0.96 | 0.97 | 1.27 | 0.46 | 0.53 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.74 | -0.71 | -0.53 | -0.58 | -0.58 | 0.60 | 0.18 | -0.20 | -0.60 | -0.55 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.28 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -1185.93 | -5.38 | -2.35 | -3.19 | -11.75 | -2.16 | -8.15 |
Net cash position: cash ($22M) exceeds total debt ($226487)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.56 | 3.56 | 3.45 | 4.87 | 12.46 | 13.10 | 1.01 | 1.82 | 2.70 | 3.92 | 5.10 |
| Quick Ratio | 3.56 | 3.56 | 3.45 | 4.87 | 12.46 | 13.10 | 1.01 | 1.77 | 2.67 | 3.89 | 5.06 |
| Cash Ratio | 3.37 | 3.37 | 3.29 | 4.42 | 10.00 | 12.07 | 0.55 | 1.05 | 1.92 | 3.13 | 4.04 |
| Asset Turnover | — | 0.36 | — | — | 0.01 | — | 0.00 | 0.07 | 0.06 | 0.06 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 6462.14 | — | 463.78 | 84.63 | 69.30 | 671.71 | 575.11 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 670.2% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $2M | $150M | $122M | $113M | $65M | $45M | $43M | $40M | $40M | $38M |
Clinical Milestone Funding Dependency
Based on reported figures, NEUP trades at a P/S ratio of 1.58, which appears to reflect speculative market sentiment rather than fundamental value, given the company's reliance on non-recurring milestone payments rather than a sustainable, recurring revenue stream typical of established pharmaceutical entities.
The negative P/E of -19.87 underscores the company's current status as a pre-profit R&D vehicle where traditional valuation metrics provide little utility. Investors should monitor whether the current P/B of 0.26 indicates a deep value opportunity or a market consensus that the underlying intellectual property lacks long-term commercial viability.
As reported in financial statements, NEUP's ROIC has swung violently from a positive 160.2% in 2025Q3 to a negative 10.0% by 2026Q3, illustrating the extreme sensitivity of capital efficiency to the timing of milestone-based revenue recognition rather than operational excellence.
This volatility suggests that the company is not yet compounding capital in a meaningful way, as returns are dictated by lumpy licensing inflows. Analysts should view these fluctuations as a byproduct of the firm's early-stage development phase rather than a reflection of sustainable return-generating capabilities.
According to recent SEC filings, the company's DPO reached 382 days in 2026Q3, a figure that suggests an aggressive management of supplier leverage to preserve cash, though this may be unsustainable as the firm scales its clinical trial operations.
The lack of consistent asset turnover data further complicates the assessment of operational efficiency. Investors should be wary of relying on these metrics, as they appear to be heavily influenced by the company's unique, non-recurring revenue structure rather than standard commercial activity.
Based on the reported figures, NEUP maintains a current ratio of 14.31 as of 2026Q3, yet this high liquidity metric appears misleading given the consistent quarterly cash burn and the absence of recurring revenue streams to support ongoing research and development activities.
While the quick ratio mirrors the current ratio, indicating a lack of inventory dependence, the company's reliance on external capital to fund its negative operating margins remains a critical vulnerability. The current liquidity position may provide a temporary cushion, but it does not mitigate the long-term risk of capital exhaustion.
As reported in financial statements, the P/S ratio is the most commonly misapplied metric for NEUP, as it obscures the non-recurring nature of the company's licensing revenue and fails to account for the high probability that future inflows will be lumpy and unpredictable.
Using P/S to value a clinical-stage biotech firm like NEUP ignores the reality that revenue is a proxy for milestone achievement rather than commercial market penetration. Analysts should instead focus on cash burn rates and the probability-weighted net present value of the clinical pipeline to better assess the firm's true economic potential.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEUP stock.
Neuphoria Therapeutics Inc.'s current P/E ratio is -15.0x. This places it at the 50th percentile of its historical range.
Neuphoria Therapeutics Inc.'s return on equity (ROE) is -1.6%. The historical average is -45.4%.
Based on historical data, Neuphoria Therapeutics Inc. is trading at a P/E of -15.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Neuphoria Therapeutics Inc. has 100.0% gross margin and -7.2% operating margin.